Search This Blog

Thursday, December 11, 2025

An "Existential Crisis" To Close 2025

 By Michael Every of Rabobank

The Fed delivered what was expected – a 25bps rate cut to 3.75% and a deep public split over whether it should cut further because the labor market is weakening or keep policy tight because inflation is too high. The Fed will also buy $40bn of T-Bills just after stopping QT, but this is not to be seen as QE, nor as having any impact on monetary policy - and QE was a neutral “asset swap”, not a balance sheet expansion that juiced asset prices. See here for the take of our US Strategist Philip Marey, who concludes that as Trump takes a firmer grip of the Fed ahead, rates are likely to fall more than some expect.

The ECB’s Lagarde spoke of “Europe's existential crisis” and didn’t think the level of ECB rates could do anything about it. She underlined estimates that internal trade barriers due to national regulations on top of the EU’s own amount to an effective tariff of 110% on services and 60% on goods traded between member states. “Everybody wants to sugarcoat, gold-plate and do just a bit more,” yet on reforms, “There will be pushback from multiple corners… from people who say: ‘We’re very happy in our corner of Europe, leave us alone.’” (As ‘Teresa Ribera is ‘not interested in competition,’ complains jilted Brussels bubble’ – but that didn’t stop the EU from just raiding China’s Temu over a foreign subsidy allegation.) Lagarde underlined the need for a transformative capital markets union and joint Eurobonds for defence funding, seeing this as opportunity.

The BoC left rates on hold at 2.25% and seems to think it’s done, yet admitted it‘s difficult to “assess the underlying momentum of the economy,” given US tariffs’ impact over time. See here for more from Molly Schwartz.

The RBA, hawkish on Tuesday, prompting market chatter of rate hikes in 2026, will look at the jobs numbers today (-21.3K vs +20K expected) and perhaps rethink. But what of asset prices as the AFR notes, ‘Why this mum bought her 11-year-old son a townhouse.’ Only one? Tsk!

Today, BoE Governor Bailey will testify to Parliament’s Covid Inquiry. Will we see questions about the Bank’s response, e.g., why didn’t it use macroprudential measures on mortgage lending at the same time as deep rate cuts and massive QE? There are key lessons to be learned for when the next, inevitable ‘nobody saw it coming’ crisis hits - will central banks have a clearer idea of what they are *for* by then?

Meanwhile, as so often reiterated here, the backdrop against which all central banks pretend to know what they’re doing is getting increasingly unpredictable.

In geoeconomics, Mexico imposed 50% tariffs on China and other Asian economies –exactly the Trump Plan we predicted: next, Canada(?) Against that backdrop, the USTR said he seeks a “constructive” reset on trade with China, which launched a satellite super factory to rival Starlink and added domestic AI chips to its official procurement list for the first time. However, Ford suppliers received China's new streamlined rare-earth licenses - but German automakers were notably excluded so far. Indonesia is resisting US trade demands on critical minerals and energy it sees risking its relations with China and Russia. On the other hand, India reportedly offered the US its ‘best-ever’ deal, as D.C. pushes farm access in trade negotiations, as the US Soybean association president meanwhile stated that Trump’s farm aid plan for them is “A band-aid on an open wound.” The UK’s PM also told Parliament that a return to the EU customs union would “unravel” new UK trade deals: yes, some things are zero sum. Trade can be one of them.

In geopolitics, US Representative Massie has introduced a bill to pull America out of NATO, which speaks to the times if not its likelihood of passage. It’s nonetheless noted that Trump’s recent verbal attacks on Europe will force it to speed up post-America defence plans, with belated recognition that the era of America’s “security guarantee” for Europe is over. It seems Europe will have to pay much more than it has budgeted for the military by 2035, and a lot sooner. That’s as a report suggested a parallel US National Security Strategy to split up the EU and establish a new global “C5” of the US, China, Russia, India, and Japan, leaving Europe out of the power loop.

Germany’s Chancellor Merz nonetheless underlined he still wants the US as partner, and if Trump "can't make sense of this institution or the structure of the EU," the US can still cooperate with member states, and “Germany is, of course, first and foremost one of them.” Divide et impera.

Regardless, the EU is pressing harder for the passage of its €210bn Ukraine loan scheme, which Lagarde says is now the “closest” to being legal so far - is that something compliance officers like hearing? She added the new version should reassure investors it “does not amount to confiscation” - but as this money is clearly not going to be given back to Russia, it’s unclear how. Indeed, Belgium is demanding an extra cash buffer as wergild against expected Russian retaliation against it and Euroclear. And that’s presuming retaliation stays in that dimension – the FT reports on fears of a wider Russian campaign of sabotage to infrastructure and businesses ahead, which potentially comes with its own cost in terms of lower growth and higher inflation.

Muddying the waters for the EU in terms of its desire to adhere to global institutions, the International Court of Justice granted Russia’s counterclaim in a genocide case vs Kyiv. The potential implication, according to some, is that any warfare can be genocide if civilians are involved. Elsewhere, the US threatened to sanction the International Criminal Court unless it promises not to prosecute President Trump.

In Latin America, the US seized an Iranian oil tanker off the coast of Venezuela after smuggling Nobel peace prize laureate Machado out of the country: she called for democracies to “fight for freedom,” which may not be metaphorical. In Brazil, a bill that could reduce ex-President Bolsonaro’s prison time has advanced in Congress. In Bolivia, leftist ex-president Arce was just arrested for corruption a month after leaving office. And China pledged foreign aid to the region with no “political conditions” – it seems the Western Hemisphere may be ideologically, if not physically, contested.

In the Indo-Pacific, China says it seeks a “fair and just maritime order” in the South China Sea, which it claims; the ongoing Japan-China spat is seen as having no off-ramp; a Telegraph report claims China’s hypersonic missiles would destroy the US Navy in a fight over Taiwan - as the US Navy Secretary called for a “wartime footing” in US weapons production; and Thailand-Cambodia border fighting rages on as Trump signals he might try to intervene.

In the Middle East, there are reports of a build-up of US military jets heading towards the Middle East, as others say Iran has started mass production of ballistic missiles again. Trump will also delay unveiling his Gaza Board of Peace members until 2026, and it’s reported that the US is weighing hitting the UN Palestinian refugee agency UNWRA with terrorism-related sanctions.

If you think that’s too much information to fit into a Global Daily, try writing it(!) Moreover, consider this is just one day, in one week, in one month, in what has been a non-stop year for wild news headlines. 2026 doesn’t look like it’s going to get any easier. Quite the opposite, in fact.

You might not see it all as an existential crisis, just a ‘volatile trading backdrop’, but trying to keep up with just that part for readers can certainly prompt one for those who try!

https://www.zerohedge.com/markets/existential-crisis-least-some

Rep. Stevens Files Impeachment Articles Against Robert F. Kennedy Jr.

 by Jonathan Turley,

I recently wrote about the absurdity of the Democratic effort to impeach Defense Secretary Pete Hegseth. I have also opposed Republican calls to impeach judges. Impeachment mania has returned for the midterm elections. However, on the scale of utter lunacy, the call to impeach Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. takes the cake.

This effort is being led by Rep. Haley Stevens (D-MI), who is running for Senate and has decided that the best way to achieve that distinction is to turn the constitutional process into a mockery.In academic writings, testimony (including at the impeachment hearings of Clinton, Trump, and Biden), and litigation (as the lead counsel in the last judicial impeachment trial), I have long argued against such ill-defined articles for impeachment.Stevens is seeking to impeach Kennedy for turning “his back on science”:

“Today, I formally introduced articles of impeachment against Robert F. Kennedy, Jr. RFK Jr. has turned his back on science and the safety of the American people. Michiganders cannot take another day of his chaos.”

Many Americans welcome Kennedy’s efforts to make food healthier and to challenge the status quo at HHS. Others, like Stevens, have strong objections to those policies. This is a good-faith and worthy debate for us to have. For years, there was little debate on such questions.

Indeed, in the prior Administration, to challenge prevailing expert opinion was to risk being labeled a wingnut or conspiracist. The very same people who are calling for Kennedy’s head were part of the mob denouncing dissenters in the scientific community, or those who remained silent as scientists were fired, censored, and cancelled.

The most anti-science position was to demand compliance with the orthodoxy of the pandemic years. Take Jay Bhattacharya, who co-authored the Great Barrington Declaration and was a vocal critic of COVID-19 policies.

Bhattacharya is now the 18th director of the National Institutes of Health and is working with Kennedy to change the culture of groupthink among health researchers and regulators in the government.

Bhattacharya was censored, blacklisted, and vilified due to his opposing views on health policy, including opposing wholesale shutdowns of schools and businesses. He was recently honored with the prestigious “Intellectual Freedom” award from the American Academy of Sciences and Letters.

He was one of many who were blacklisted for challenging pandemic policies. It did not matter that positions once denounced as “conspiracy theories” have been recognized or embraced by many.

Some argued that there was no need to shut down schools, which has led to a crisis in mental illness among the young and the loss of critical years of education. Other nations heeded such advice with more limited shutdowns (including keeping schools open) and did not experience our losses.

Others argued that the virus’s origin was likely the Chinese research lab in Wuhan. That position was denounced by the Washington Post as a “debunked” coronavirus “conspiracy theory.” The New York Times Science and Health reporter Apoorva Mandavilli called any mention of the lab theory “racist.”

Federal agencies now support the lab theory as the most likely based on the scientific evidence.

Likewise, many questioned the efficacy of those blue surgical masks and supported natural immunity to the virus — both positions were later recognized by the government.

Others questioned the six-foot rule, which shut down many businesses, as unsupported by science. In congressional testimony, Dr. Anthony Fauci recently admitted that the rule “sort of just appeared” and “wasn’t based on data.” Yet not only did it result in heavily enforced rules (and meltdowns) in public areas, but the media further ostracized dissenting critics.

Again, Fauci and other scientists did little to stand up for these scientists or call for free speech to be protected. As I discuss in my new book, The Indispensable Right,” the result is that we never really had a national debate on many of these issues and the result was massive social and economic costs.

The point is that these attacks were “turning your back on science” by crushing dissent and stopping any meaningful debate on these issues. These same figures were wrong on the science, but now seek to lead another mob to impeach those seeking to change policies and practices at HHS and NIH.

Democrats clearly oppose Kennedy’s initiatives. Fine. Use legislation and the power of the purse to push back on those efforts if you have a majority in Congress. What you should not do is use impeachment to achieve what you could not achieve during the confirmation process.

Many on the left appear to have a particular hatred for Kennedy as a type of fallen angel, a progressive from an iconic Democratic family who rejected the party’s intolerance and direction. Hell hath no fury like a party scorned.

The pledges of new impeachments are ominous going into the midterm elections, where Democrats appear to be promising more of the same dysfunctional efforts to use this constitutional process for raw partisan advantage. Even with those who oppose Trump Administration policies, it is hard to believe that a majority of Americans want to return to the same chaos of the first term.

https://www.zerohedge.com/political/impeachment-articles-filed-against-robert-f-kennedy-jr

Putin Doubles Down On Backing Maduro As US Prepares To Seize More Oil Tankers

 The Kremlin confirmed that Russian President Vladimir Putin spoke by phone with Venezuelan President Nicolás Maduro on Thursday and reassured him of Moscow's support, at a moment he's facing likely regime change action at the hands of US military might.

Putin expressed support for Maduro's rule "in the face of growing external pressure," but they also discussed their advancing a strategic partnership and the areas of ongoing economic and energy projects. Moscow has long stood by Caracas' side throughout years of growing isolation and sanctions.

The Kremlin statement added that "Putin expressed solidarity with the Venezuelan people and reaffirmed his support for the Maduro government's policy of safeguarding national interests and sovereignty amid mounting external pressure."

Wednesday saw elite American special forces operators board and seize a Venezuelan oil tanker. They were filmed rappelling onto the ship's deck from a helicopter, with rifles at the ready.

This has serious repercussions for Russia too, given Moscow has been a longtime trading partner with Caracas, and it raises the potential that Russian tankers in the Caribbean could be intercepted.

Perhaps even more notably, Reuters reports that Washington is preparing to intercept more ships transporting Venezuelan oil following the seizure of a tanker this week, as it increases pressure on Venezuelan President Nicolas Maduro, six sources familiar with the matter said on Thursday.

Further direct interventions by the U.S. are expected in the coming weeks targeting ships carrying Venezuelan oil that may also have transported oil from other countries targeted by U.S. sanctions, such as Iran, according to the sources familiar with the matter who declined to be named due to the sensitivity of the issue.

Last weekend Russian Deputy Foreign Minister Sergei Ryabkov said that his country would stand "shoulder to shoulder" with Venezuela in this time of crisis, but didn't offer anything concrete.

"This is primarily due to the desire to assert the unquestioning dominance of the United States in the region, this is a trademark of the Trump administration," Ryabkov explained.

According to some more of the latest developments via Newsweek:

  • Initial reports on Wednesday cited U.S. officials saying the Coast Guard carried out the tanker seizure under international maritime law, targeting vessels tied to alleged illicit PDVSA-linked crude shipments.
  • U.S President Donald Trump later confirmed the seizure, hinting that “other things are happening,” but offered no further details.
  • A senior Trump administration official described the move as a “judicial enforcement action on a stateless vessel” last docked in Venezuela.
  • Oil prices jumped on the news: Brent crude rose 0.8 percent to $62.35 a barrel, and West Texas Intermediate climbed to $58.46.
  • Analysts warn the seizure may further strain U.S.–Venezuela relations and deter shippers already wary of handling sanctioned Venezuelan crude.
  • Maduro has long accused Washington of seeking to overthrow him and seize Venezuela’s vast oil reserves; the nation’s production has fallen from over 2 million barrels a day to roughly 1 million.
  • The seizure comes after Trump renewed threats of intervention by land, air, or sea, including a recent U.S. fighter jet flyover near Venezuelan airspace.
  • Caracas condemned the action as “international piracy” and “brazen theft,” accusing the U.S. of trying to control its natural resources.
  • Trump called the tanker the “largest ever” seized by the U.S.

Some hawks have long viewed Venezuela as a Latin American satellite state of Russian influence...

While Russia has been a longtime ally of President Maduro, it is unlikely to come to his defense in any direct way, also given the delicate and sensitive efforts to improve bilateral ties with Washington amid talks to de-escalate the Ukraine war. This despite Caracas having formally pleaded for more help from Moscow of late, including arms deliveries.

https://www.zerohedge.com/geopolitical/putin-doubles-down-backing-maduro-after-us-seizes-oil-tanker

US 'Answers' China By Sending Pair Of Nuclear-Capable Bombers Over Sea Of Japan

 On Wednesday we detailed that Japanese and South Korean fighter jets quickly answered a joint Russian-Chinese long-range bomber flight over the Western Pacific. Chinese J-16 fighter jets, two Russian Su-30 fighters and an A-50 early-warning aircraft were part of the provocative flight, which also passed close to South Korea. Russia's Defense Ministry (MoD) had confirmed its Tu-95MS strategic bombers and China’s H-9 strategic bombers conducted the eight hour flight over the Sea of Japan, the East China Sea and the Western Pacific - but that at no time was any country's airspace violated.

Washington has quickly injected itself into the ratcheting situation, coming amid a diplomatic and economic standoff between Japan and China, by sending US nuclear capable bombers on patrol over the Sea of Japan.

Handout photo from Japan's Ministry of Defense 

Japan's government confirmed its fighter planes joined the US bomber patrol, which was clearly a show of force signaling China and Russia.

"We confirmed the strong resolve of Japan and the United States not to allow any unilateral change of the status quo by force, as well as the readiness of the Self-Defense Forces and the US military," Japan's Defense Ministry said in a statement.

The fresh exercise with the US Air Force was conducted in "an increasingly severe security environment surrounding our country" - it said.

The flight included a pair of US B-52 bombers, escorted by Japanese F-35 stealth fighters and three F-15 jets. Beijing had presented the prior, longer flight as routine and in accord with international law.

"We consider it a grave concern from the standpoint of Japan's security," Japan's Chief of Staff, Joint Staff General Hiroaki Uchikura, commented of the prior Chinese-Russian aerial patrol.

Chinese Foreign Ministry spokesperson Guo Jiakun responded dismissively, saying "The Japanese side has no need to make a fuss about nothing or to take this personally."

All of this is taking place as a carrier strike group is sailing close to Japan, and after weekend PLA drills saw monitoring Japanese planes come under radar lock. The US State Department has condemned this, saying "China's actions are not conducive to regional peace and stability."

Much of these tensions hearken back to Prime Minister Sanae Takaichi's words to parliament last month wherein she left open the possibility of Japan sending its military to defend Taiwan in the event of a Chinese invasion.

Amid economic and diplomatic retaliation, including on the tourism sector, Japan was hoping for more vocal help from the Trump administration while feeling Beijing's wrath, but alas it hasn't come in a political form. However, the US sending bombers for an 'exercise' does seem fairly muscular.

https://www.zerohedge.com/geopolitical/us-answers-china-sending-pair-nuclear-capable-bombers-over-sea-japan

Senate Fails To Advance GOP Healthcare Plan After Collins, Murkowski, Hawley & Sullivan Break Ranks

 Update (1311ET): The Senate has failed to advance the GOP's healthcare plan which would allow Obamacare subsidies to expire, and would give millions of Americans $1,000 - $1,500 in health savings accounts. 

The plan failed by a vote of 51 yeas to 48 nays. Republicans needed 60 votes to pass it. Breaking ranks with the GOP were Republican Sens. Collins, Hawley, Murkowski and Sullivan. 

Looks like they did have a plan...

🚨 BREAKING:

Next up: the Democrats' plan

*  *  *

Authored by Lawrence Wilson & Nathan Worcester via The Epoch Times (emphasis ours),

The Senate is poised for a Dec. 11 vote on competing measures to resolve the standoff over extending the expiring subsidies for Obamacare.

Senate Minority Leader Chuck Schumer (D-N.Y.) and Senate Majority Leader John Thune (R-S.D.).

Both are likely to fall along party lines, and to fail to reach the 60-vote threshold required to advance legislation in the Senate.

The subsidies, officially known as enhanced premium tax credits, were created as a temporary measure in 2021 to blunt the economic impact of the COVID-19 national health emergency.

Originally offered for two years, the enhanced subsidies were further extended for three years and will expire at the end of this month.

Democrats, fearing that allowing the subsidies to expire now would cause financial hardship and cause millions of Americans to drop their health coverage, have proposed another three-year extension.

Democrats have put forward the cleanest, fastest, most realistic solution, a three-year extension of the current tax credits,” Senate Minority Leader Chuck Schumer (D-N.Y.) said on Dec. 9.

Republicans, saying that the billions spent on these additional subsidies have contributed to rapidly rising insurance premiums and have given rise to opportunities for fraud, oppose an extension that does not address those issues.

The bill [Democrats] are going to put on the floor will fail,” Senate Majority Leader John Thune (R-S.D.) told reporters on Dec. 9.

Republicans have proposed an alternative plan. It would replace the enhanced subsidies with a cash payment to eligible enrollees, to be placed in a Health Savings Account. The original Obamacare subsidies, distinct from the enhanced subsides, would remain in place.

Schumer on Dec. 9 criticized the proposal as “dead on arrival.”

Enhanced Subsidies

The enhanced subsidies enacted in 2021 expanded eligibility for Obamacare, offering subsidies for wage earners well into the middle class.

The original Obamacare subsidies are open to people making between 100 percent and 400 percent of the federal poverty level. That equates to a household income of between $32,150 and $128,600 for a family of four.

The enhanced subsidies increased the amount of the subsidies, removed the income limit, and capped out-of-pocket premium payments at 8.5 percent of household income. Some low-income enrollees are eligible for plans with no premium payment under the coverage expansion.

Obamacare enrollment more than doubled after the enhanced subsidies were introduced.

Standoff

Democrats pushed for a permanent extension of the enhanced subsidies early in the fall, refusing to authorize continued spending to fund the government until Republicans agreed to negotiate over this and other health-care-related proposals.

Republicans refused to consider the extension during the shutdown.

The government shutdown, which lasted for 43 days, ended when eight Democratic Senators voted with Republicans to approve stopgap funding to reopen the government, but on the condition that their party be given a vote this month on extending the subsidies.

Schumer revealed the Democrats’ proposal for a three-year extension on Dec. 4.

Sens. Mike Crapo (R-Idaho) and Bill Cassidy (R-La.) released their plan on Dec. 8, and Republicans elected to present it for a vote alongside the Schumer plan on Dec. 11.

Other plans have been proposed by Senate Republicans, by bipartisan groups of House members, and by the House New Democrat Alliance.

Compromise Seekers

The latest compromise proposal has been put forward by Rep. Brian Fitzpatrick (R-Pa.), joined by a bipartisan group of House members.

Fitzpatrick introduced a discharge petition that, if successful, could force the House to vote on his proposal. A discharge petition requires support from 218 House members.

The Fitzpatrick plan would extend the enhanced premium tax credits through 2027 to insulate consumers from sudden rate increases. It includes some measures to check fraud by unscrupulous insurance brokers and rein in some practices of pharmacy benefit managers, the middlemen in the prescription drug supply chain.

The measure has the support of several moderate House members, including Reps. Jared Golden (D-Maine), Michael Lawler (R-N.Y.), Don Bacon (R-Neb.), Thomas Suozzi (D-N.Y.), and Robert Bresnahan (R-Pa.).

The subsidies have taken on a sense of urgency as the Jan. 1 premium increases draw nearer. “This is personal to a lot of us because these are our friends and our neighbors that are losing sleep over this,” Fitzpatrick said.

Sen. Thom Tillis (R-N.C.) applauded the effort, saying it seemed similar to a three-year ramp-down of the subsidies that he suggested.

Tillis told The Epoch Times on Dec. 10 that any measure would need roughly equal support from both parties because hardliners on both sides would be likely to reject a compromise.

Sen. Richard Blumenthal (D-Conn.) said, “Compromise should never be a dirty word.”

Sen. Angus King (I-Maine) said: “This should be a bipartisan. Let’s get together and figure this out.”

Sen. Josh Hawley, who has proposed no tax on health care premiums, deductibles, or copays, said lawmakers should explore every option for bringing down the cost of health care.

“I think it should be hard to go home and say to people whose premiums are doubling, ‘You know, we just couldn’t quite get it done,’” he said.

https://www.zerohedge.com/political/senate-vote-dueling-health-care-bills-tackling-expiring-obamacare-subsidies

Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer

 

While overall survival remains immature, results so far show a clear trend in favor of Roche’s giredestrant.

Roche’s investigational hormonal therapy giredestrant significantly outperformed standard therapy in a late-stage trial of patients with early breast cancer, potentially setting the oral drug up to become the new standard of care.

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant in more than 4,100 medium- or high-risk patients with stage I–III, ER-positive, EGFR2-negative breast cancer. Results showed the pill lowered the risk of death or invasive disease recurrence by 30% at three years.

At this time point, 92.4% of giredestrant-treated patients remained alive and free of invasive disease, as opposed to 89.6% in comparators treated with other endocrine agents. Giredestrant’s benefit remained consistent across various subgroups. Roche’s analysis of the study’s primary endpoint showed that 6.7% of patients on giredestrant had developed invasive cancer or died, according to reporting by Fierce Biotech. This was compared to 9.4% of patients in the control arm, for a hazard ratio of 0.7—equaling 30%.

The analysis of LidERA’s primary endpoint showed that 6.7% of patients on giredestrant had developed invasive cancer or died, compared to 9.4% of people in the control arm.

Overall survival findings were immature at the time of the readout, but the pharma reported a “clear positive trend” in favor of giredestrant. The company will continue to follow study participants for overall survival outcomes. Roche presented these findings at the 2025 San Antonio Breast Cancer Symposium (SABCS).

The company said giredestrant was well-tolerated, with side effects that were manageable and consistent with what had been established for the drug in prior studies.

Roche will share lidERA’s results with global health authorities, Chief Medical Officer Levi Garraway said in a prepared statement on Wednesday.

Designed to be orally available, giredestrant is a selective estrogen receptor degrader—more commonly known as SERD—that works by disrupting the binding of estrogen to its corresponding receptor. This mechanism of action triggers the destruction of estrogen receptors, in turn slowing or outright stopping the growth of cancer cells.

Aside from lidERA, Roche is also testing giredestrant in the Phase III evERA Breast Cancer study, which combined the oral SERD with everolimus and compared it against standard endocrine therapy plus everolimus. Results released in October showed the investigational combo reduced the risk of death or disease progression by 44%. This efficacy improved to 62% when focusing on patients with ESR1 mutations.

The pharma is likewise running the Phase III persevERA Breast Cancer study of giredestrant in ER-positive, HER2-negative locally advanced or metastatic breast cancer. The trial combines the SERD pill with Pfizer’s Ibrance and compares it against letrozole plus Ibrance. Primary completion is expected this month

https://www.biospace.com/drug-development/roches-oral-serd-cuts-death-risk-by-30-in-early-stage-breast-cancer

Zealand Bets up to $2.5B in Metabolic Pact With Chinese Biotech

 

Also on Thursday, Zealand held its Capital Markets Day in London, outlining the strategy for its weight management franchise in the near-term, including launching five products by 2030.

Already one of the leading biotechs in the obesity space, Zealand Pharma has teamed up with China’s OTR Therapeutics to advance next-generation drugs for the condition and other metabolic disorders in a partnership worth up to $2.5 billion.

The back-heavy deal involves a $20 million upfront payment from Zealand, which could increase to $30 million under certain unspecified conditions. OTR Therapeutics will be eligible for preclinical, development, regulatory and sales milestones that could hit up to $2.5 billion, the bulk of which will come from the partnership’s potential commercial performance. The Chinese biotech will also receive tiered single-digit royalties on worldwide net sales of any product under the agreement that reaches the market.

The deal marks an expansion into oral small-molecule therapeutics for Zealand, but keeps the biotech within molecular targets where it already has experiense, Chief Scientific Officer Utpal Singh said in a statement.

In exchange for the investment, Zealand will be able to leverage OTR’s proprietary small-molecule platform to advance novel therapies for several metabolic disease targets. The partners did not say which indications they plan to prioritize, though Singh in his statement noted that the agreement is in line with the company’s strategy to bring new treatment options to “people who are overweight, with obesity, and other metabolic diseases.”

Zealand already has two powerhouse partners behind it, securing the biotech’s place as a leader in the obesity space. In March this year, Roche fronted $1.65 billion and promised up to $3.6 billion in milestones to partner with the Danish biotech and gain the right to co-develop and co-commercialize the amylin analog petrelintide for weight loss. Zealand’s presence in the metabolic disease space stretches as far back as 2011, when Boehringer Ingelheim took notice of survodutide (then called ZP2929), a dual-acting agonist of the GLP-1 and glucagon receptors.

Zealand anticipates two late-stage topline readouts for survodutide in the front half of 2026, while petrelintide will deliver Phase II data next year.

Also on Thursday, Zealand held its Capital Markets Day in London, outlining the strategy for its weight management franchise in the near-term, with an eye toward becoming a leader in the metabolic health space in the coming years.

To achieve this goal, Zealand will work to speed its discovery and development process such that by 2030, the company will be able to launch five products and build a “robust” pipeline of more than 10 investigational therapies.

“We are redefining weight management for a new era,” CEO Adam Steensberg said in a statement, “moving beyond the weight loss Olympics toward solutions that support the everyday needs, aspirations, and overall well-being of people living with overweight, obesity, and metabolic imbalance.”

https://www.biospace.com/business/zealand-bets-up-to-2-5b-in-metabolic-pact-with-chinese-biotech